Ongoing Mesothelioma Clinical Trials
Clinical trials are designed to test new treatments as efficiently as possible. Part of this design means only a certain number of patients can be accepted into each study. Once a mesothelioma study reaches this enrollment target, no additional mesothelioma patients are accepted. The study is still considered to be ongoing, as doctors continue treating and monitoring existing study patients.
Some clinical trials release preliminary study results during this time period. For instance, the CheckMate 743 clinical trial did this in 2020. CheckMate 743 investigated the use of two immunotherapy drugs compared to standard chemotherapy treatment.
The immunotherapy drug combination (nivolumab and ipilimumab) performed better than standard chemotherapy. Patients treated with the immunotherapy drugs lived about four months longer than those receiving chemotherapy.
After reviewing the study results, the U.S. Food and Drug Administration (FDA) approved the immunotherapy drugs. Specifically, nivolumab and ipilimumab were approved for the treatment of inoperable pleural mesothelioma.
If you or a loved one are considering enrolling in a clinical trial, you can find open studies on our Clinical Trials – Recruiting page.
Ongoing Mesothelioma Clinical Trials Not Recruiting Patients
Provided below is a list of mesothelioma trials that are no longer accepting new patients.
Note: The information below is provided by ClinicalTrials.gov.
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Conditions: Mesothelioma
Last Updated: September 11, 2025
Status: Active, not recruiting
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Conditions: Mesothelioma
Last Updated: September 8, 2025
Status: Active, not recruiting
Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease
Conditions: Mesothelioma
Last Updated: September 8, 2025
Status: Active, not recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 6, 2025
Status: Active, not recruiting
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
Conditions: Mesothelioma
Last Updated: September 6, 2025
Status: Active, not recruiting
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Conditions: Mesothelioma
Last Updated: September 5, 2025
Status: Active, not recruiting
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 4, 2025
Status: Active, not recruiting
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Conditions: Mesothelioma
Last Updated: August 28, 2025
Status: Active, not recruiting
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions: Mesothelioma
Last Updated: August 22, 2025
Status: Active, not recruiting
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma
Last Updated: August 20, 2025
Status: Active, not recruiting
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: August 20, 2025
Status: Active, not recruiting
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma
Last Updated: August 20, 2025
Status: Active, not recruiting
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: August 14, 2025
Status: Active, not recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: August 12, 2025
Status: Active, not recruiting
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Mesothelioma
Last Updated: August 8, 2025
Status: Active, not recruiting
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: July 24, 2025
Status: Active, not recruiting
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Conditions: Mesothelioma
Last Updated: July 22, 2025
Status: Active, not recruiting
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: June 25, 2025
Status: Active, not recruiting
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: June 6, 2025
Status: Active, not recruiting
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: May 16, 2025
Status: Active, not recruiting
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Conditions: Mesothelioma
Last Updated: May 16, 2025
Status: Active, not recruiting
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
Conditions: Mesothelioma
Last Updated: May 16, 2025
Status: Active, not recruiting
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Conditions: Mesothelioma
Last Updated: May 8, 2025
Status: Active, not recruiting
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: February 5, 2025
Status: Active, not recruiting
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: October 8, 2024
Status: Active, not recruiting
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Conditions: Mesothelioma
Last Updated: September 30, 2024
Status: Active, not recruiting
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 20, 2024
Status: Active, not recruiting
KZR-261 in Subjects With Advanced Solid Malignancies
Conditions: Mesothelioma
Last Updated: August 15, 2024
Status: Active, not recruiting
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: March 28, 2024
Status: Active, not recruiting
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Conditions: Mesothelioma
Last Updated: December 14, 2023
Status: Active, not recruiting
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Conditions: Mesothelioma
Last Updated: October 20, 2023
Status: Active, not recruiting
